IHS Chemical Week

Regions :: Western Europe :: Switzerland

Lonza Rides Biopharma Wave

12:09 PM MDT | July 30, 2007 | Alex Scott

Lonza has unveiled a robust set of 2006 results, bolstered by a substantial contribution from the company’s fast-growing biopharmaceuticals business. Lonza’s biopharma sales increased 31% last year, to SF468 million ($375 million), the company says. Growing demand and a strong project pipeline supported a number of capacity expansions and related acquisitions in the biopharma field, Lonza says. Lonza’s exclusive synthesis and biopharmaceuticals division, which includes the biopharma business, recorded a 36% increase in 2006 Ebit, to SF193...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa